🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 3 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
05/03/2025 9,74 9,90 9,42 9,81 +1,24% 4,93% 1.347.400
04/03/2025 10,33 10,33 9,64 9,69 -7,71% 6,68% 969.500
03/03/2025 10,88 11,10 10,32 10,50 -3,58% 7,17% 1.117.300
28/02/2025 10,37 10,94 10,37 10,89 +10,22% 5,50% 1.786.300
27/02/2025 10,25 10,43 9,86 9,88 -2,56% 5,61% 1.141.500
26/02/2025 11,59 11,68 9,92 10,14 -0,98% 15,19% 1.664.100
25/02/2025 10,21 10,48 10,01 10,24 +0,79% 4,60% 1.159.700
24/02/2025 11,03 11,07 10,12 10,16 -8,22% 8,61% 1.208.700
21/02/2025 11,50 11,66 10,81 11,07 +3,07% 7,39% 1.239.200
20/02/2025 10,97 11,08 10,63 10,74 -3,24% 4,10% 1.515.900
19/02/2025 11,17 11,69 10,94 11,10 +1,28% 6,76% 4.738.500
18/02/2025 12,80 12,97 10,65 10,96 -16,34% 18,09% 4.657.800
14/02/2025 12,92 13,49 12,73 13,10 +3,15% 5,88% 401.700
13/02/2025 12,11 12,73 12,00 12,70 +5,83% 6,03% 527.700
12/02/2025 11,72 12,03 11,55 12,00 +0,25% 4,10% 525.900
11/02/2025 12,36 12,52 11,89 11,97 -3,86% 5,10% 532.100
10/02/2025 12,61 12,75 12,26 12,45 -0,80% 3,89% 467.100
07/02/2025 13,01 13,06 12,55 12,55 -3,54% 3,88% 400.500
06/02/2025 13,72 13,72 12,98 13,01 -4,13% 5,39% 375.800
05/02/2025 13,42 13,80 13,24 13,57 +1,19% 4,17% 403.300
04/02/2025 13,21 13,74 13,02 13,41 +1,59% 5,41% 1.408.800
03/02/2025 12,53 13,54 12,53 13,20 +2,33% 8,06% 872.700
31/01/2025 13,35 13,45 12,89 12,90 -3,59% 4,19% 547.500
30/01/2025 13,16 13,56 13,03 13,38 +2,84% 3,99% 436.200
29/01/2025 13,07 13,32 12,83 13,01 -0,61% 3,75% 482.400
28/01/2025 13,45 13,49 13,07 13,09 -2,82% 3,09% 519.900
27/01/2025 13,07 13,76 13,05 13,47 +2,36% 5,43% 703.500
24/01/2025 13,32 13,55 12,97 13,16 -1,28% 4,35% 889.800
23/01/2025 13,30 13,63 12,88 13,33 -0,52% 5,63% 1.067.900
22/01/2025 14,05 14,08 13,40 13,40 -5,23% 4,84% 991.400